Loading...
Bilateral Trade Intelligence · $1.7K Total Trade · 2 Foreign Suppliers · 2 Indian Buyers · DGFT Verified · Updated March 2026
India imported $1.7K worth of pharmaceutical formulations from Cameroon across 3 verified shipments, from 2 foreign suppliers to 2 Indian buyers. The top suppliers are TEKA PHARMA SARL ($1.6K) and MBACHAM FON WILFRED ($123). The leading products are Artesunate ($2K). Average shipment value: $578.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Artesunate | $1.7K | 100.0% |
India imports 1+ pharmaceutical formulations from Cameroon with a combined trade value of $1.7K. Key products include Artesunate ($2K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 3 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Cameroon, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Cameroon buyers, regulatory requirements, and logistics for that specific product corridor. Products include Artesunate ($2K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
2 Indian pharmaceutical companies export finished formulations to Cameroon. Leading exporters include Teka Pharma Sarl, Mbacham Fon Wilfred, . The top exporter accounts for 92.9% of total India–Cameroon pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Cameroon and India has experienced modest activity from 2022 to 2026. During this period, India imported a total of $2,000 USD worth of finished pharmaceutical formulations from Cameroon, comprising three shipments. The primary product imported was artesunate, a medication used to treat malaria. This limited trade volume indicates a nascent and underdeveloped trade relationship in the pharmaceutical sector between the two nations.
Cameroon's contribution to India's pharmaceutical imports remains negligible, accounting for a mere fraction of India's total pharmaceutical import value. The imports from Cameroon are exclusively finished pharmaceutical formulations, specifically artesunate, highlighting a narrow product focus. This suggests that Cameroon has yet to establish a significant presence in India's diverse pharmaceutical import market.
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) or notable trade agreements affecting the pharmaceutical import sector between Cameroon and India. The lack of substantial developments during this period reflects the limited engagement and potential for growth in this trade corridor.
2 companies in Cameroon import pharmaceutical formulations from India. Top buyers include Mylan Laboratories Limited, Strides Pharma Science Limited, . The largest buyer accounts for 92.9% of India–Cameroon pharma imports. Source: Indian Customs (DGFT).
Registration process, GMP requirements, import documentation
For Cameroonian pharmaceutical companies to export finished formulations to India, they must navigate the CDSCO registration process. This involves appointing an authorized Indian agent to represent them in India. The registration requires submission of Form 40, along with a comprehensive dossier that includes:
The timeline for approval can vary, but it typically ranges from several months to over a year, depending on the completeness of the application and the need for additional information or inspections.
India requires that manufacturing sites in Cameroon adhere to GMP standards recognized by the World Health Organization (WHO). This includes compliance with quality management systems, proper documentation, and regular inspections. The CDSCO may conduct inspections of the manufacturing facility to ensure adherence to these standards before granting approval for importation.
To import pharmaceutical products into India, Cameroonian exporters must provide:
These documents ensure compliance with Indian regulations and facilitate the smooth importation of pharmaceutical products.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Cameroon to India are currently limited to artesunate, a single product used in the treatment of malaria. This indicates a lack of diversification in the product range and suggests that Cameroon has yet to establish a broader presence in India's pharmaceutical import market.
Given the limited scope of imports from Cameroon, there is currently no significant presence of innovator drugs, novel formulations, or advanced therapies being imported into India from Cameroon. The trade is predominantly focused on a single generic product, artesunate, without notable innovation or specialization.
The minimal importation of pharmaceutical products from Cameroon to India can be attributed to several factors:
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These tariffs are subject to periodic revisions and can impact the competitiveness of imported pharmaceutical products.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Cameroon concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but there are no bilateral agreements that offer preferential treatment for pharmaceutical products.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the rejection of patents on new forms of known substances unless they demonstrate enhanced efficacy. This provision has been a subject of debate and has implications for the importation of certain pharmaceutical products. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs in India, which can affect the pricing strategies of imported pharmaceutical products.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Cameroon to India are typically transported by sea, given the limited volume of trade. The primary ports involved are:
Transit times can vary but generally range from 20 to 30 days, depending on the shipping route and vessel schedules. The reliability of these routes is generally good, but subject to seasonal variations and geopolitical factors.
Douala Port in Cameroon is the primary export hub for pharmaceutical products, offering facilities for containerized cargo and adherence to international shipping standards. In India, ports like Mumbai, Chennai, and Kolkata are equipped with specialized facilities for handling pharmaceutical imports, including temperature-controlled storage and customs clearance processes.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes:
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain products to meet specific demands, such as:
As of March 2026, there are no significant Cameroonian pharmaceutical companies operating in India. The limited trade volume and lack of established partnerships suggest that Cameroonian companies have yet to explore the Indian market extensively
India exported pharmaceuticals worth $1.7K to Cameroon across 3 verified shipments.
1. TEKA PHARMA SARL — $1.6K. 2. MBACHAM FON WILFRED — $123. Total: 2 suppliers.
1. MYLAN LABORATORIES LIMITED — $1.6K. 2. STRIDES PHARMA SCIENCE LIMITED — $123. 2 buyers total.
1. Artesunate ($1.7K, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $1.7K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$578 per consignment across 3 shipments.
2 Indian companies. Largest: TEKA PHARMA SARL with $1.6K.
TransData Nexus covers 2 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 3 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Exporters
2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists